TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03380845

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fraxel Restore
Description: Non-ablative Laser. In the study, one side of the face will be treated with Fraxel Restore monthly for three months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractora
Description: Fractional Radiofrequency Microneedling Device. In the study, one side of the face will be treated with Fractora monthly for three months.
Study: NCT01043952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol is used as an anesthetic drug on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is used as an anesthetic drug on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil is used as analgesic drug, as a part of the total intravenous anaesthesia, on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil is used as analgesic drug, as a part of the total intravenous anaesthesia, on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral Index Monitor
Description: Bispectral Index Monitor (BIS monitor integrated in the IntelliVue Patient monitor MP70, Philips) is used to monitor the depth of anesthesia. The values this monitor reports are used as an aid in evaluating the response of the single patient to the administered anesthetics, and as a guide in adjusting the dosing of anesthetics. We follow the algorithm from: http://www.biseducation.com/assets.aspx?ac=1 (ASA Practice Advisory White Paper)
Study: NCT01575457

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Career Counseling and Motivational Interviewing
Description: The Healthy Futures Program is an interactive, multi-session training program. There will be participants in 3 different intervention tracks (College/vocational school, Job, and Career Planning). Activities for all three tracks will occur simultaneously. The intervention group will receive the interactive, multi-session training program including newsletters and workshops. Comparison group participants will receive newsletters and be invited to participate in college and career planning workshops.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Career Counseling and Motivational Interviewing
Description: The Healthy Futures Program is an interactive, multi-session training program. There will be participants in 3 different intervention tracks (College/vocational school, Job, and Career Planning). Activities for all three tracks will occur simultaneously. The intervention group will receive the interactive, multi-session training program including newsletters and workshops. Comparison group participants will receive newsletters and be invited to participate in college and career planning workshops.
Study: NCT03857581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Subjects will be randomly assigned to clozapine or olanzapine and followed for up to 12 weeks with weekly visits.
Study: NCT02405481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEPA III
Study: NCT04296994

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QL1706
Description: QL1706（PSB205） is a bi-functional product that has been engineered to contain two unique monoclonal antibodies.
Study: NCT03148847

Intervention type: OTHER
Intervention: Baseline care
Study: NCT01389245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed™ TX
Description: OsseoSpeed™ TX implants of lengths 8-17 mm
Study: NCT05225155

Intervention type: DRUG
Intervention: Enoxaparin
Description: Women with thrombophilia were treated with 40 mg daily of enoxaparin (treated group), initiated on the day of embryo transfer, up to week 36 of gestation
Study: NCT00559091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Ribavirin will be administered orally, twice daily, in the morning and evening with food. The dose selected is 400 mg AM and 600 mg PM. Intrapatient dose escalations can also be performed in defined circumstances. The maximal dose administered will be 1000 mg AM and 1000 mg PM.
Study: NCT03424226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: a diuretic and commonly used medication for prevention and treatment of acute mountain sickness

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: a diuretic and commonly used medication for prevention and treatment of acute mountain sickness
Study: NCT01851967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MoodGYM
Description: MoodGYM, a publicly-available online CBT program developed by the Centre for Mental Health Research at The Australian National University has been shown by multiple studies to be effective in reducing symptoms of depression. MoodGYM consists of five interactive modules. Participants will be asked to complete one module each week and progress through the program sequentially.
Study: NCT04390685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment
Description: Treatment with tacrolimus ointment once daily for one year following axillary lymph node dissection
Study: NCT02038322

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: The Stork - Conception Aid
Study: NCT02339948

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: 8.0 Gy per fraction for 5 fractions for a total of 40 Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: 8.0 Gy per fraction for 5 fractions for a total of 40 Gy
Study: NCT04340050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-SARS-CoV-2 convalescent plasma
Description: Infusion of one unit of anti-SARS-CoV-2 convalescent plasma \~300 mL over 4 hours
Study: NCT06165588

Intervention type: OTHER
Intervention: Tour de France
Description: Participating in the Tour de France as cyclist
Study: NCT02406755

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: one-sensory self care (Todo Dia®)
Description: daily use of odorless body moisturizer (Todo Dia® - Natura)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: multisensory self care (Todo Dia®)
Description: daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura) + audiovisual stimulus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bi-sensory self care (Todo Dia®)
Description: daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura)
Study: NCT01606878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT02241863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Description: Supportive intervention: care giver, health care providers, and patient's family members (including disease knowledge, treatment t of the disease, medication problems or adverse effects, the importance of medication adherence, supervision taking medications by the patients as prescribed). patient education: about the disease and treatment, consuming regularly the pills motivational intervening, self-monitoring planning. Patients will attend in five motivational interviewing sessions regularly to facilitating and engaging intrinsic motivation within the patients in order to change medication adherence behavior.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine counseling
Study: NCT01701492

Intervention type: OTHER
Intervention: Questionnaire
Description: A one-time assessment using both performance-based measures as well as both self- and parent-report questionnaires.

Intervention type: OTHER
Intervention: Questionnaire
Description: A one-time assessment using both performance-based measures as well as both self- and parent-report questionnaires.

Intervention type: OTHER
Intervention: Neurocognitive Evaluation
Description: A one-time neurocognitive evaluation conducted in the Psychology Clinic

Intervention type: OTHER
Intervention: Neurocognitive Evaluation
Description: A one-time neurocognitive evaluation conducted in the Psychology Clinic
Study: NCT02510391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PIPA
Description: Parent-training Intervention for Preschoolers with Anxiety (PIPA) is a behaviorally based modular treatment program for emotional and behavioral problems in young children. 12 sixty minute sessions will be delivered weekly. This intervention employs a modular format following a treatment algorithm in which therapy modules are selected by the therapist and supervisor on a session-by-session basis to address the most pressing clinical needs. Minimum session requirements for parent training/education and fear hierarchy/exposure are set to insure adequate dose of core exposure and response prevention for anxiety across cases.
Study: NCT01237054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-NaF PET
Description: The patient will receive 5mCi of F-18 NaF IV (intravenous) bolus, followed by a \~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of \~20 seconds. Serial dynamic imaging (2 minutes/bed position) will be obtained over a 1-hour period. The patient will be permitted an imaging break until a static PET/CT is performed beginning at 2-hours post F-18 NaF injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DCE-MRI
Description: An FDA (Food and Drug Administration) approved gadolinium chelate (e.g. Magnevist, Berlex Laboratories, NJ, USA) will be administered intravenously at 3 cc/sec using an automated pump injector (Medrad, Pittsburgh, PA, USA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-FDG PET/CT
Description: The 18F-FDG injection procedure will be injected and be followed by a \~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of \~20 seconds. The injection site will be evaluated pre- and post administration for any reaction (e.g. bleeding, hematoma, redness, or infection). Whole body (vertex to toes) static PET/CT imaging will be performed beginning at 1-hour, and again at 2-hours post injection.
Study: NCT01125163

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement
Description: multivitamin that provides 2mg/kg/day of iron given orally to infants when they are tolerating 120 ml/dg/day of preterm formula or fortified breast milk until they reach 36 weeks adjusted postmenstrual age.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: multivitamin
Description: daily oral multivitamin without iron until 36 weeks adjusted postmenstrual age
Study: NCT02562378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab and non-pegylated liposomal doxorubicin
Description: 3 Cohorts (3+3 design):~Cohort 1- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (45 mg/m2) IV~Cohort 2- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (50 mg/m2) IV~Cohort 3- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (60 mg/m2) IV
Study: NCT03233386

Intervention type: BEHAVIORAL
Intervention: Mantente REAL
Description: substance abuse prevention curriculum for adolescents

Intervention type: BEHAVIORAL
Intervention: Mantente REAL
Description: substance abuse prevention curriculum for adolescents

Intervention type: BEHAVIORAL
Intervention: Mantente REAL
Description: substance abuse prevention curriculum for adolescents
Study: NCT02942615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: limit heart dose
Description: limit heart dose: Dmean≤6Gy,V30≤20%,V10≤50%
Study: NCT02055963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21.
Study: NCT03391284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetominophen
Description: INTRAVENOUS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetominophen
Description: INTRAVENOUS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: ORAL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: ORAL
Study: NCT01767103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferriprox®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferriprox®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferriprox®
Study: NCT03804983

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid Closed Loop (HCL)
Description: Participants will use Control-IQ with Hybrid Closed Loop (HCL) with their own insulin parameters during the entire two-week study, including the 72-hour ski admission and the at-home study collection times. Parameters will be reduced 20% during the ski admission to adjust for the increased activity.
Study: NCT04609696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan: Tablet
Description: Danicopan (200 milligrams) will be administered orally on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan: Tablet
Description: Danicopan (200 milligrams) will be administered orally on Day 1.
Study: NCT04183478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-001
Description: K-001 is an antitumor active substance (peptidoglycan) which is prepared from the fermentation product of marine microorganism. K-001 is the Chinese first class new drug and get patent licensing in China, America and Japan.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo which looks the same as K-001 in apparence
Study: NCT01284543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the Tan EndoGlide to insert donor graft
Description: Using the Tan EndoGlide to insert donor graft into the eye
Study: NCT03148847

Intervention type: OTHER
Intervention: Referential's dissemination
Study: NCT04571632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelumab
Description: Avelumab (200mg/10mL solution) will be administered by intratumoral injection at a maximum total dose of 40 mg (= 2 ml of a 200mg/10ml solution) on day 1 followed by a subsequent intratumoral injections on day 15, 29, 43, 57 and 71.~Total administered dose of avelumab (200mg/10mL solution) will be up to 2.0 mL per treatment. Injected volume per lesion will range from 0.05 mL for lesions \< 0,5 cm to 2.0 mL for lesions \> 5 cm in longest diameter.~Injection of all lesions in individual patients will not be required.
Study: NCT01606878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane Hydrochloride
Description: Given IV
Study: NCT01217502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self management program
Description: Professional caregivers will be trained in offering a self management program to aged persons with a dual sensory impairment. Duration of the program: 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self management program
Description: Learning and practicing skills necessary to carry on an active and emotionally satisfying life in the face of the dual sensory impairment
Study: NCT01284543

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Busin Glide for delivery of the donor graft
Description: Use of the forceps for delivery of the donor graft into the eye
Study: NCT03860688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TED + glucose
Description: Teduglutide, up to 0.05mg/kg, subcutaneous, single dose Glucose, 25g, oral, single dose
Study: NCT01295125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XenMATRIX mesh
Description: Use of XenMATRIX mesh in the repair of contaminated ventral hernia repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open abdominal ventral hernia repair
Description: Abdominal ventral hernia repair with native tissue
Study: NCT00561327

Intervention type: DRUG
Intervention: losartan
Description: Daily treated with losartan 100mg for at least the past 2 months (retrospective, no new drug treatment/ intervention)
Study: NCT02511756

Intervention type: DEVICE
Group type: OTHER
Intervention: Computed tomography X-ray system
Description: Contrast-enhanced computed tomography of liver metastases
Study: NCT03943485

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The uterine manipulator which is primarily used in laparoscopic hysterectomy to accurately locate the colpotomy site. We adopted this device in abdominal hysterectomy.
Description: The uterine manipulator is primarily used in laparoscopic hysterectomy to accurately locate the colpotomy site. We hypothesized that adoption of a uterine manipulator would help the surgeon to better identify the colpotomy site by moving the uterus cranially and thus providing better visualization of the colpotomy site.
Study: NCT02135198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg AZD7325
Description: A single 2 mg oral dose of AZD7325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg AZD7325
Description: A single 2 mg oral dose of AZD7325

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2 mg AZD7325
Description: A single 2 mg oral dose of AZD7325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg AZD7325
Description: A single 10 mg oral dose of AZD7325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg AZD7325
Description: A single 10 mg oral dose of AZD7325

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10 mg AZD7325
Description: A single 10 mg oral dose of AZD7325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single oral dose
Study: NCT02085551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy by the Indigo System
Study: NCT00647816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride Extended-Release Capsules 160 mg
Description: 160mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inderal® LA Capsules 160 mg
Description: 160mg, single dose fasting
Study: NCT02327481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Laparoscopic Surgery
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, 3D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2D Laparoscopic Surgery
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, 2D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
Study: NCT00643253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LC and Electronic Prompt
Description: Women will receive: a) International Board of Certified Lactation Consultant (IBCLC) education/counseling during the pre-natal, intra-partum and post-hospital discharge period to promote early and continued exclusive breastfeeding. The protocol specifies 2 prenatal meetings, a hospital visit, and a home visit if indicated and accepted, and; b) Electronic Medical Record Prompts- will appear on the prenatal record 5 times throughout the pregnancy. They are brief discussion points re breastfeeding that the provider is asked to raise with their patients.
Study: NCT01415674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib 40mg per os daily for 14 to 28 days, depending on the date of the surgery
Study: NCT00464464

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive-behavioral therapy
Description: The therapy will consist of 10 weekly individual cognitive-behavioral treatment sessions, lasting 1 hour each and modified to meet the unique needs of each individual with PD.
Study: NCT01023321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0555
Description: single ascending doses, oral solution
Study: NCT01606878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study: NCT01023321

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose, oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0555
Description: multiple dose, oral solution, 7 or 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: multiple dose, oral solution, 7 or 14 days